| Project/Area Number |
16K19946
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 大腸癌 / 癌間質 / 間質 / VCAN |
|---|
| Outline of Final Research Achievements |
This study aimed to examine the clinicopathological, prognostic and functional roles of VCAN expression cancer stroma in CRC, using microarray datasets and FFPE tissues. We initially attempted to determine the localization of VCAN transcript and VCAN protein using expression datasets derived from laser-microdissected CRC samples and FACS-purified CRC cell populations, followed by immunohistochemistry for FFPE specimens. VCAN was found to be expressed specifically by cancer-associated fibroblasts in the tumor microenvironment, and VCAN immunohistochemical staining was detected specifically in cancer stroma. Importantly, we found that the expression of VCAN in mRNA transcript and protein levels was each associated with poor disease-free survival in stage II-III CRC, independent of conventional clinicopathological parameters.
|
| Academic Significance and Societal Importance of the Research Achievements |
大腸癌は全がんにおいて死亡・罹患数が最も上位の癌腫のひとつであり、さらに増加傾向とされている。効果的で安全な個別化医療を提供することが重要である。本研究で着目したVCAN遺伝子発現およびVCANタンパク発現は、ステージ2-3大腸癌術後の再発リスクの高い症例において特に高発現していることがわかった。今後は、大腸癌間質、癌関連線維芽細胞におけるVCANの機能的な意義の解明とともに、ステージ2-3大腸術後の予後バイオマーカーとして有用な可能性がある。
|
